These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9717852)
1. Pharmacoeconomics: what is it and where is it going? McCombs JS Am J Hypertens; 1998 Aug; 11(8 Pt 2):112S-119S; discussion 135S-137S. PubMed ID: 9717852 [TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
3. Using pharmacoeconomics to value pharmacotherapy. Hay JW Clin Pharmacol Ther; 2008 Aug; 84(2):197-200. PubMed ID: 18679182 [TBL] [Abstract][Full Text] [Related]
4. Report on financing the new model of family medicine. Spann SJ; Ann Fam Med; 2004 Dec; 2 Suppl 3(Suppl 3):S1-21. PubMed ID: 15654084 [TBL] [Abstract][Full Text] [Related]
5. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Lipsy RJ Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017 [TBL] [Abstract][Full Text] [Related]
7. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. Reeder CE Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244 [TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Hospital and Community Pharmacy Services. Gammie T; Vogler S; Babar ZU Ann Pharmacother; 2017 Jan; 51(1):54-65. PubMed ID: 27586430 [TBL] [Abstract][Full Text] [Related]
9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Henry D; Taylor C Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632 [TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomics and health policy. Current applications and prospects for the future. Greenberg PE; Arcelus A; Birnbaum HG; Cremieux PY; LeLorier J; Ouellette P; Slavin MB Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):425-32. PubMed ID: 10662390 [TBL] [Abstract][Full Text] [Related]
12. Drug therapy: safety, effectiveness, and economics. Brandys J Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340 [TBL] [Abstract][Full Text] [Related]
13. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Jönsson B Pharmacoeconomics; 2004; 22 Suppl 4():5-10. PubMed ID: 15876007 [TBL] [Abstract][Full Text] [Related]
14. Principles of pharmacoeconomic analysis of drug therapy. Freund DA; Dittus RS Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037 [TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomics: state of the art in 1997. Schulman KA; Linas BP Annu Rev Public Health; 1997; 18():529-48. PubMed ID: 9143730 [TBL] [Abstract][Full Text] [Related]
16. Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials. Schulman KA; Ohishi A; Park J; Glick HA; Eisenberg JM Keio J Med; 1999 Mar; 48(1):1-11. PubMed ID: 10206013 [TBL] [Abstract][Full Text] [Related]
17. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394 [TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics comes of age? Walley T; Breckenridge A Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057 [TBL] [Abstract][Full Text] [Related]